Keio Innovation Initiative (KII) has invested in iXgene, a Keio University School of Medicine venture company developing novel therapies for malignant brain tumors using genome-edited iPS cells, through a fund managed by KII. iXgene will use the funds raised to advance pre-clinical trials for malignant brain tumor applications, aiming for early clinical entry of genome-edited iPS-derived neural stem cells.

For more information, please see the press release.
https://prtimes.jp/main/html/rd/p/000000041.000018580.html